Mediwound Ltd
MDWD18.620USD
-0.150-0.80%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
238.74MMarket Cap
LossP/E TTM
More Details of Mediwound Ltd Company
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Mediwound Ltd Info
Ticker SymbolMDWD
Company nameMediwound Ltd
IPO dateMar 20, 2014
CEOGonen (Ofer)
Number of employees111
Security typeOrdinary Share
Fiscal year-endMar 20
Address42 Hayarkon Street
CityYAVNE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code8122745
Phone972779714100
Websitehttps://www.mediwound.com/
Ticker SymbolMDWD
IPO dateMar 20, 2014
CEOGonen (Ofer)
Company Executives of Mediwound Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Ofer Gonen
Mr. Ofer Gonen
Chief Executive Officer, Director
Chief Executive Officer, Director
182.10K
+84.44%
Mr. Nachum (Homi) Shamir
Mr. Nachum (Homi) Shamir
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Jeremy Feffer
Mr. Jeremy Feffer
Managing Director
Managing Director
--
--
Ms. Hani Luxenburg
Ms. Hani Luxenburg
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Stephen T. Wills, CPA
Mr. Stephen T. Wills, CPA
Independent Director
Independent Director
--
--
Dr. Ety Klinger, Ph.D.
Dr. Ety Klinger, Ph.D.
Chief Research and Development Officer
Chief Research and Development Officer
--
--
Dr. Shmulik Hess
Dr. Shmulik Hess
Chief Operating Officer, Chief Commercial Officer
Chief Operating Officer, Chief Commercial Officer
--
--
Dr. Robert J. Snyder
Dr. Robert J. Snyder
Chief Medical Officer
Chief Medical Officer
--
--
Mr. David Fox
Mr. David Fox
Independent Director
Independent Director
--
--
Dr. Vickie R. Driver, M.D.
Dr. Vickie R. Driver, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Ofer Gonen
Mr. Ofer Gonen
Chief Executive Officer, Director
Chief Executive Officer, Director
182.10K
+84.44%
Mr. Nachum (Homi) Shamir
Mr. Nachum (Homi) Shamir
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Jeremy Feffer
Mr. Jeremy Feffer
Managing Director
Managing Director
--
--
Ms. Hani Luxenburg
Ms. Hani Luxenburg
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Stephen T. Wills, CPA
Mr. Stephen T. Wills, CPA
Independent Director
Independent Director
--
--
Dr. Ety Klinger, Ph.D.
Dr. Ety Klinger, Ph.D.
Chief Research and Development Officer
Chief Research and Development Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2023
FY2022
FY2021
FY2020
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
USA
15.46M
76.47%
EU and other international markets
4.76M
23.53%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Dec 5
Updated: Fri, Dec 5
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Clal Biotechnology Industries Ltd
11.55%
Investor AB
6.80%
Yelin Lapidot Provident Funds Management Ltd
6.32%
Rosalind Advisors, Inc.
5.84%
HOLD Alapkezelo Zrt
5.49%
Other
64.00%
Shareholders
Shareholders
Proportion
Clal Biotechnology Industries Ltd
11.55%
Investor AB
6.80%
Yelin Lapidot Provident Funds Management Ltd
6.32%
Rosalind Advisors, Inc.
5.84%
HOLD Alapkezelo Zrt
5.49%
Other
64.00%
Shareholder Types
Shareholders
Proportion
Investment Advisor
22.91%
Holding Company
11.55%
Hedge Fund
10.81%
Investment Advisor/Hedge Fund
8.44%
Private Equity
6.80%
Venture Capital
2.95%
Corporation
2.17%
Individual Investor
1.42%
Research Firm
0.83%
Other
32.12%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
135
5.72M
44.57%
+391.20K
2025Q2
127
6.70M
61.97%
-1.10M
2025Q1
129
6.76M
62.72%
-1.01M
2024Q4
118
7.26M
67.33%
+161.02K
2024Q3
115
7.34M
70.49%
+440.76K
2024Q2
91
5.75M
66.40%
+288.97K
2024Q1
69
5.35M
61.63%
-376.56K
2023Q4
61
5.55M
64.63%
+32.10K
2023Q3
62
5.26M
71.22%
+1.01M
2023Q2
64
5.23M
72.67%
+954.42K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Clal Biotechnology Industries Ltd
1.48M
11.55%
--
--
Sep 30, 2025
Investor AB
872.09K
6.8%
--
--
Jun 30, 2025
Yelin Lapidot Provident Funds Management Ltd
816.74K
6.37%
-41.26K
-4.81%
Jun 30, 2025
Rosalind Advisors, Inc.
407.06K
3.17%
-99.83K
-19.69%
Jun 30, 2025
HOLD Alapkezelo Zrt
703.43K
5.49%
+703.43K
--
Sep 22, 2025
T. Rowe Price Associates, Inc.
369.08K
2.88%
+214.12K
+138.19%
Jun 30, 2025
Israel Biotech Fund
378.62K
2.95%
-172.63K
-31.32%
Mar 15, 2025
BlackRock Institutional Trust Company, N.A.
388.27K
3.03%
-45.72K
-10.54%
Jun 30, 2025
Deep Insight Limited Partnership
278.18K
2.17%
-273.07K
-49.54%
Mar 15, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
ARK Israel Innovative Technology ETF
1.64%
Invesco NASDAQ Future Gen 200 ETF
0.59%
iShares Micro-Cap ETF
0.03%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
ARK Israel Innovative Technology ETF
Proportion1.64%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.59%
iShares Micro-Cap ETF
Proportion0.03%
iShares Russell 2000 Growth ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 19, 2022
Merger
7→1
Dec 19, 2022
Merger
7→1
Dec 19, 2022
Merger
7→1
Dec 19, 2022
Merger
7→1
Date
Type
Ratio
Dec 19, 2022
Merger
7→1
Dec 19, 2022
Merger
7→1
Dec 19, 2022
Merger
7→1
Dec 19, 2022
Merger
7→1
FAQs
Who are the top five shareholders of Mediwound Ltd?
The top five shareholders of Mediwound Ltd are:
Clal Biotechnology Industries Ltd holds 1.48M shares, accounting for 11.55% of the total shares.
Investor AB holds 872.09K shares, accounting for 6.80% of the total shares.
Yelin Lapidot Provident Funds Management Ltd holds 816.74K shares, accounting for 6.37% of the total shares.
Rosalind Advisors, Inc. holds 407.06K shares, accounting for 3.17% of the total shares.
HOLD Alapkezelo Zrt holds 703.43K shares, accounting for 5.49% of the total shares.
Clal Biotechnology Industries Ltd holds 1.48M shares, accounting for 11.55% of the total shares.
Investor AB holds 872.09K shares, accounting for 6.80% of the total shares.
Yelin Lapidot Provident Funds Management Ltd holds 816.74K shares, accounting for 6.37% of the total shares.
Rosalind Advisors, Inc. holds 407.06K shares, accounting for 3.17% of the total shares.
HOLD Alapkezelo Zrt holds 703.43K shares, accounting for 5.49% of the total shares.
What are the top three shareholder types of Mediwound Ltd?
The top three shareholder types of Mediwound Ltd are:
Clal Biotechnology Industries Ltd
Investor AB
Yelin Lapidot Provident Funds Management Ltd
Clal Biotechnology Industries Ltd
Investor AB
Yelin Lapidot Provident Funds Management Ltd
How many institutions hold shares of Mediwound Ltd (MDWD)?
As of 2025Q3, 135 institutions hold shares of Mediwound Ltd, with a combined market value of approximately 5.72M, accounting for 44.57% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -17.39%.
What is the biggest source of revenue for Mediwound Ltd?
In FY2024, the -- business generated the highest revenue for Mediwound Ltd, amounting to -- and accounting for --% of total revenue.
